Extending beyond cancer applications, hepatocyte-derived exosomal glucose transporter1 (GLUT1) can be used as a biomarker to identify the risk of non-alcoholic steatohepatitis (NASH) and diagnose stage two liver fibrosis [104]. Here, SLC2A1 is linked to metabolic dysfunction-associated steatohepatitis.